Mallinckrodt has posted positive efficacy results in its Phase III trial of MNK-155, an investigational extended-release oral formulation of hydrocodone and acetaminophen, in the management of moderate to moderately severe acute pain where the use of an opioid analgesic is appropriate. MNK-155 met the primary endpoint in this study. Mallinckrodt also completed a series of other clinical trials evaluating pharmacokinetics, safety and abuse liability of MNK-155. These data, including the Phase II...